[07 February 2014]
Products Affected - Description
Ketamine injection, Bedford
50 mg/mL, 10 mL vial, package of 10 (NDC 55390-0475-10)
Ketamine injection, Hospira
100 mg/mL, 5 mL vial, package of 10 (NDC 00409-2051-05)
Reason for the Shortage
- Ben Venue has stopped production in its plant in Bedford, Ohio and will close in early 2014. Ben Venue supplies multiple sterile injectable products for Bedford Laboratories. Supplies of product that has already been manufactured will continue to be released until inventory is depleted. Bedford Laboratories has a small number of products manufactured elsewhere that are not affected by this closure.
- JHP and Mylan Institutional could not provide a reason for the shortage.
Ketamine injection, Hospira
50 mg/mL, 10 mL vial, package of 10 (NDC 00409-2053-10)
Ketalar injection, JHP
10 mg/mL, 20 mL vials (NDC 42023-0113-10)
50 mg/mL, 10 mL vials (NDC 42023-0114-10)
100 mg/mL, 5 mL vials (NDC 42023-0115-10)
Ketamine injection, JHP
10 mg/mL, 20 mL vials (NDC 42023-0137-10)
50 mg/mL, 10 mL vials (NDC 42023-0138-10)
100 mg/mL, 5 mL vials (NDC 42023-0139-10)
Ketamine injection, Mylan Institutional
10 mg/mL, 20 mL vials (NDC 67457-0181-20)
50 mg/mL, 10 mL vials (NDC 67457-0001-10)
100 mg/mL, 10 mL vials (NDC 67457-0108-10)
Estimated Resupply Dates
- Bedford has ketamine 50/mL vials on long-term back order and the company cannot estimate a release date. Ben Venue manufactured dobutamine for Bedford.
- Hospira has ketamine 100 mg/mL 5 mL vials on back order with an estimated release date of late-March 2014.
February 7, 2014; November 11, 2013; August 27, 2013; July 23, 2013; July 9, 2013; June 25, 2013; June 13, 2013; May 30, 2013; April 10, 2013; March 27, 2013; March 7, 2013; February 22, 2013; February 6, 2013; January 9, 2013; November 13, 2012; October 12, 2012; September 10, 2012; July 20, 2012; May 24, 2012; April 18, 2012; March 23, 2012; March 1, 2012; February 24, 2012; February 7, 2012; February 1, 2012; January 31, 2012, University of Utah, Drug Information Service. Copyright 2014, Drug Information Service, University of Utah, Salt Lake City, UT.
This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.
« Back to Drug Shortage Product Bulletins